Sophia Genetics raises $110 million in new funding round
01 October 2020
Share this article
Alychlo has supported Sophia Genetics, global leader in Data-Driven Medicine, for 5 years as an important investor. The company has now raised another $110 million, led by major health-tech fund aMoon. Alychlo also participated in this Series F round.
The funds will be used to further support Sophia’s global expansion to US and Asian markets and to increase the platform’s multimodal capabilities and adoption by healthcare institutions worldwide.
Full press release:
